Dong-E-E-Jiao Co.,Ltd. (000423.SZ) Bundle
Curious whether Dong-E-E-Jiao Co., Ltd. (000423.SZ) is a value play or a risk-laden specialty producer? Start with the numbers: Q3 2025 revenue fell to 1.72 billion CNY (down 5.59% QoQ) while TTM revenue sits at 6.12 billion CNY (up 4.61% YoY) after a standout 2024 revenue of 5.92 billion CNY (+25.57% vs. 2023); the market prices those sales at a P/S 5.13 within a 31.40 billion CNY market cap. Profitability shows strength-Q3 net profit margin hit 26.58% (+16.68% QoQ), EPS is 0.57 CNY, ROE 14.60% and ROA 9.11% with TTM net income of 1.68 billion CNY-while the balance sheet reveals total assets of 12.75 billion CNY, liabilities of 2.78 billion CNY, a net cash position with 8.17 billion CNY in cash, and a conservative debt-to-equity of 0.28, supporting robust liquidity ratios (current 3.0, quick 2.5, cash 2.0) and an interest coverage around 20. Valuation measures show a P/E of 18.77, forward P/E 16.60, EV/EBITDA 57.41, dividend yield 4.69% and an estimated intrinsic value of 53.52 CNY per share versus the market price of 48.05 CNY. Key risks and upside are clear-heavy reliance on the Ejiao line and donkey-hide supply contrasts with expansion opportunities in international markets, product diversification, R&D, strategic M&A and e-commerce-read on to unpack which of these facts matter most for investors.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Revenue Analysis
Dong-E-E-Jiao reported revenue of 1.72 billion CNY in Q3 2025, a sequential decline of 5.59% from Q2 2025. On a trailing twelve months (TTM) basis, revenue is 6.12 billion CNY, representing a 4.61% year-over-year increase. The company recorded full-year revenue of 5.92 billion CNY in 2024, a notable 25.57% increase versus 2023.- Q3 2025 revenue: 1.72 billion CNY (-5.59% QoQ)
- TTM revenue: 6.12 billion CNY (+4.61% YoY)
- FY 2024 revenue: 5.92 billion CNY (+25.57% YoY)
- Revenue per employee: ~1.49 million CNY (total workforce: 4,095)
- Price-to-Sales (P/S) ratio: 5.13
- Market capitalization: 31.40 billion CNY
| Metric | Value | Change / Note |
|---|---|---|
| Q3 2025 Revenue | 1.72 billion CNY | -5.59% QoQ |
| TTM Revenue | 6.12 billion CNY | +4.61% YoY |
| FY 2024 Revenue | 5.92 billion CNY | +25.57% YoY |
| Revenue per Employee | ~1.49 million CNY | 4,095 employees |
| Price-to-Sales (P/S) | 5.13 | Market valuation vs. sales |
| Market Capitalization | 31.40 billion CNY | Reflects investor confidence |
- Sequential dip in Q3 2025 suggests near-term demand softness or seasonal effects; monitor next quarter for recovery or trend confirmation.
- TTM and FY 2024 growth indicate underlying revenue expansion despite quarterly volatility.
- High P/S (5.13) shows premium valuation - investors are pricing in growth or margin resilience relative to current sales levels.
- Revenue per employee (~1.49M CNY) points to solid productivity for a consumer/health supplement manufacturer, but scalability and margin leverage should be tracked.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Profitability Metrics
Key profitability indicators for Q3 2025 highlight strong margins and efficient capital use at Dong-E-E-Jiao Co.,Ltd.
- Net profit margin (Q3 2025): 26.58% - up 16.68% vs. prior quarter
- EPS (Q3 2025): 0.57 CNY - unchanged from prior quarter
- ROA (Q3 2025): 9.11%
- ROE (Q3 2025): 14.60%
- Operating profit margin (Q3 2025): 14.26%
- Net income (TTM): 1.68 billion CNY
| Metric | Q3 2025 | Prior Quarter | TTM / Notes |
|---|---|---|---|
| Net profit margin | 26.58% | 22.79% (calculated; implies 16.68% increase) | - |
| Earnings per share (EPS) | 0.57 CNY | 0.57 CNY | - |
| Return on assets (ROA) | 9.11% | - | Reflects asset efficiency |
| Return on equity (ROE) | 14.60% | - | Strong shareholder returns |
| Operating profit margin | 14.26% | - | Indicates effective cost management |
| Net income (TTM) | 1.68 billion CNY | - | Trailing twelve months |
- Improved net profit margin (+16.68% QoQ) suggests higher pricing power or lower non-operating costs in Q3 2025.
- Stable EPS implies earnings per share growth matched share count and dilution trends.
- ROA of 9.11% and ROE of 14.60% point to efficient deployment of assets and equity.
- Operating margin at 14.26% supports sustainable operating profitability before financing and taxes.
Exploring Dong-E-E-Jiao Co.,Ltd. Investor Profile: Who's Buying and Why?
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Debt vs. Equity Structure
As of September 30, 2025, Dong-E-E-Jiao Co.,Ltd. exhibits a capital structure characterized by a dominant equity base and minimal leverage. Key headline figures drive the company's conservative financial posture and liquidity strength.| Metric | Value (CNY) | Notes |
|---|---|---|
| Total Assets | 12,750,000,000 | Reflects balance sheet scale as of 2025-09-30 |
| Total Liabilities | 2,780,000,000 | Includes short- and long-term obligations |
| Shareholders' Equity | 9,970,000,000 | Calculated as Assets - Liabilities |
| Cash & Cash Equivalents | 8,170,000,000 | Net cash position on the balance sheet |
| Debt-to-Equity Ratio | 0.28 | Shows conservative leverage |
| Equity Ratio | 78.3% | Equity / Total Assets |
- Net cash position (CNY 8.17bn) provides flexibility for capex, M&A, dividends, or buybacks without recourse to new borrowing.
- Debt-to-equity ~0.28 signals low reliance on external financing and lower interest-rate sensitivity.
- Equity ratio of 78.3% indicates that the bulk of the balance sheet is funded by shareholders' capital rather than creditors.
- Minimal liabilities reduce solvency risk and improve credit profile versus peers that typically carry higher leverage.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) Liquidity and Solvency
Dong-E-E-Jiao demonstrates strong short-term liquidity and solid solvency metrics, providing investors with comfort on the company's ability to meet obligations and sustain operations.- Current ratio: 3.0 - three times more current assets than current liabilities, signaling ample short-term coverage.
- Quick ratio: 2.5 - strong immediate liquidity after excluding inventories, indicating working capital quality.
- Cash ratio: 2.0 - substantial cash and equivalents relative to current liabilities, offering cushion for near-term stress.
- Operating cash flow ratio: 1.5 - operating cash generation covers current liabilities 1.5 times, showing healthy cash conversion.
- Interest coverage ratio: 20 - operating earnings cover interest expense twentyfold, implying very low interest burden risk.
- Overall solvency: robust - leverage and long-term coverage measures point to low financial distress probability.
| Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 3.0 | Sufficient short-term asset coverage |
| Quick Ratio | 2.5 | Strong immediate liquidity (ex-inventory) |
| Cash Ratio | 2.0 | Ample cash reserves vs. current liabilities |
| Operating Cash Flow Ratio | 1.5 | Healthy cash flow from core operations |
| Interest Coverage Ratio | 20 | Very comfortable ability to meet interest payments |
| Solvency Assessment | Robust | Low risk of financial distress based on coverage and leverage |
- Investor implications: strong liquidity reduces refinancing risk and supports capital allocation flexibility (dividends, buybacks, or strategic investments).
- Risks to monitor: sustained margin compression or one-off operational shocks could erode ratios; monitor cash flow trends and any increase in leverage.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) Valuation Analysis
Dong-E-E-Jiao presents a mixed valuation profile combining moderate earnings multiples, a high EV/EBITDA, an attractive dividend yield, and an estimated intrinsic value above the current market price.- P/E (trailing): 18.77 - suggests a moderate market valuation relative to last 12 months' earnings.
- Forward P/E: 16.60 - implies expected earnings growth or earnings recovery priced in by the market.
- Intrinsic value per share: 53.52 CNY vs. current market price: 48.05 CNY - indicates potential undervaluation on intrinsic-value basis.
- EV/EBITDA: 57.41 - a high ratio that may reflect low EBITDA, significant net debt, or sector-specific premium.
- Dividend yield: 4.69% - provides steady income and enhances total-return appeal.
- Market capitalization: 31.40 billion CNY - reflects scale and investor confidence.
| Metric | Value | Interpretation |
|---|---|---|
| P/E (TTM) | 18.77 | Moderate earnings multiple |
| Forward P/E | 16.60 | Market expects improvement |
| Intrinsic value / Share | 53.52 CNY | ~11.4% above current price |
| Current market price | 48.05 CNY | Trading below intrinsic estimate |
| EV/EBITDA | 57.41 | High relative to typical benchmarks |
| Dividend yield | 4.69% | Attractive income component |
| Market cap | 31.40 billion CNY | Large-cap within domestic context |
- Gap between intrinsic value (53.52 CNY) and market price (48.05 CNY) may signal a buying opportunity if model assumptions hold.
- High EV/EBITDA (57.41) warrants scrutiny of EBITDA levels, non-operating items, and net debt - high ratio can negate the apparent equity undervaluation.
- Dividend yield of 4.69% supports income-focused investment cases, but sustainability depends on free cash flow and payout policy.
- Forward P/E (16.60) vs. trailing P/E (18.77) suggests anticipated earnings growth; validate with company guidance and industry trends.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Risk Factors
Dong-E-E-Jiao's financial profile and future performance are shaped by a concentrated product portfolio, supply-chain peculiarities, regulatory sensitivity, and competitive pressures. Below are the key risk areas investors should weigh, with supporting data points and indicators.- Product concentration: the Ejiao product family remains the core revenue driver - estimated to account for approximately 60-80% of group revenues in recent years, leaving limited revenue diversification.
- Raw-material exposure: donkey hides (ejiao raw material) are a unique and volatile input. Price swings and supply constraints can materially affect cost of goods sold and gross margins.
- Regulatory risk: shifts in policies governing traditional Chinese medicine (TCM), animal-sourced ingredients, or food & drug approvals can create operational interruptions, product recalls, or reformulation costs.
- Diversification challenges: efforts to broaden product mix (health supplements, hospital/OTC channels, branded retail) have had mixed success; non-Ejiao lines historically contribute a minority of revenue.
- Consumer cyclicality: premium health products are discretionary; during economic slowdowns, demand contraction can compress sales and inventory turnaround.
- Competitive intensity: rising competition from other TCM companies, modern pharmaceuticals, and substitutes pressures market share and pricing power.
| Indicator | Most Recent (approx.) | Why it matters |
|---|---|---|
| % Revenue from Ejiao products | ~60-80% | High product concentration increases single-segment risk |
| Estimated share of donkey-hide cost in COGS | ~30-45% | Raw-material price swings disproportionately affect margins |
| Gross margin | ~55-65% | Relatively high, but sensitive to input-cost changes |
| Net profit margin | ~15-25% | Healthy historically; vulnerable to revenue declines or cost spikes |
| Debt-to-equity ratio | ~0.1-0.4 | Conservative leverage but capital needs for R&D / diversification remain |
| Inventory days | ~120-200 days | High inventory tied to seasonal demand and raw-material sourcing |
| R&D / SG&A as % of revenue | ~8-15% | Investment to support channel expansion and brand building |
- Supply-chain shocks: outbreaks of disease, import/export restrictions, or concentrated supplier defaults can temporarily halt procurement of donkey hides or force expensive spot purchases.
- Price passthrough limits: given consumer price sensitivity, the company may not be able to fully pass higher raw-material costs to end customers, squeezing margins.
- Regulatory enforcement scenarios: bans or stricter rules on animal-sourced TCM ingredients, or elevated testing/labeling requirements, could require reformulation, relabeling, or limit sales channels.
- Diversification execution risk: expanding into new categories or geographies requires capex, marketing, and time; failure raises the probability of continued dependency on Ejiao.
- Macroeconomic sensitivity: in GDP contractions or slower consumer spending cycles, premium health-care purchases typically decline first.
- Competitive pricing pressure: increased promotions and new entrants may erode ASPs (average selling prices) and compress EBITDA margins.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Growth Opportunities
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) sits at the intersection of traditional Chinese medicine (TCM) heritage and modern consumer health trends. The company's core product (ejiao) and established supply chain give it several clear avenues to scale revenue, diversify risk and capture higher-margin segments.
- Expanding into international markets can drive revenue growth by targeting Chinese diaspora and global herbal/wellness consumers; markets with rising demand include Southeast Asia, North America and parts of Europe.
- Diversifying the product portfolio to include complementary health products (e.g., collagen-based supplements, functional foods, drinkables and beauty/cosmeceuticals) can attract new customers beyond traditional ejiao purchasers.
- Investing in R&D to develop standardized extracts, novel dosage forms and clinically validated formulations can lead to product innovation and premium pricing power.
- Strategic partnerships and acquisitions-especially of niche herbal brands, distribution platforms or overseas GMP facilities-can accelerate market entry and broaden capabilities.
- Leveraging e-commerce platforms (own DTC channels, major marketplaces and social commerce) can expand reach and reduce dependency on offline retail.
- Capitalizing on the growing global health & wellness trend and ageing populations can boost demand for tonic/immune and collagen-related products.
Key metrics that shape the company's growth potential (illustrative recent-year figures and targets):
| Metric | Recent/Reported Value | Near-term Opportunity/Target |
|---|---|---|
| Annual Revenue (FY) | RMB 8.0-8.5 billion (approx., recent FY) | +8-15% CAGR via export & new SKUs |
| Net Profit (FY) | RMB 1.2-1.6 billion (approx.) | Improve margin by 200-400 bps through premiumization |
| Gross Margin | ~55-60% | Target 58-65% with higher-margin products |
| R&D Spend | ~1.0-1.5% of revenue (current) | Raise to 2-3% to accelerate innovation |
| Online Sales Penetration | ~20-30% of revenue | Target 35-45% via omnichannel strategy |
| Export / Overseas Revenue | Low-single-digit % currently | Target 8-15% by expanding to SEA/NA/EU |
| Market Share - Ejiao Category (China) | Leading brand; estimated 25-35% share in branded segment | Maintain leadership through branding and R&D |
Practical initiatives to realize these opportunities:
- International market roll-out: prioritize regulatory approvals (FDA/EMA/ASEAN frameworks), localized packaging and partnerships with regional distributors to move from low-single-digit export share toward mid-teens within 3-5 years.
- Product portfolio diversification: launch collagen beauty lines, ready-to-drink tonic beverages and bundled health programs; pricing tiers from mass to premium to capture broader demographics.
- R&D and clinical validation: allocate incremental budget to clinical trials and formulation science to substantiate health claims-this supports premium positioning and potential reimbursement channels.
- M&A and partnerships: target complementary brands (skin/collagen, immunity, herbal supplements) and digital-health platforms to acquire customers and technical know-how quickly.
- E-commerce acceleration: optimize direct-to-consumer channels, subscription models and live commerce; aim to increase average order value (AOV) and customer lifetime value (LTV) through CRM and personalized offerings.
- Marketing and brand modernization: blend TCM authenticity with modern wellness messaging to appeal to younger cohorts while retaining core customers.
Risk-adjusted financial levers and expected impacts:
| Initiative | Investment Required | Potential Revenue Impact (3 years) | Primary Risk |
|---|---|---|---|
| Overseas expansion | RMB 200-500 million (market entries, registrations) | +RMB 500M-1.2B | Regulatory delays, cultural fit |
| New product R&D & launches | RMB 100-300 million | +RMB 300M-800M | R&D failure or low uptake |
| E-commerce & digital marketing | RMB 50-150 million | +RMB 200M-600M | Customer acquisition cost escalation |
| M&A (bolt-on) | Variable; RMB 300M+ per target | Accelerated revenue & capabilities | Integration and valuation risk |
KPIs to monitor execution and validate progress:
- Revenue CAGR (consolidated and by channel)
- Gross and net profit margins by SKU and channel
- R&D spend as % of revenue and number of new SKUs launched
- Online conversion rates, AOV, repeat purchase rate, LTV/CAC
- Export revenue share and active distribution agreements
- Brand awareness metrics in target overseas markets
For strategic alignment, refer to the company's declared direction and values here: Mission Statement, Vision, & Core Values (2026) of Dong-E-E-Jiao Co.,Ltd.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.